Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

All states should adopt updated screening protocols so more newborns with cystic fibrosis can be diagnosed in the first weeks of life, when interventions can have the greatest benefit, according to ...

Newborn screening guidelines for cystic fibrosis recommend comprehensive genetic testing to ensure timely diagnosis across ...

Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing tool that can insert ...

"Newborn screening for cystic fibrosis has been universal in the U.S. since 2010; however, there is significant variation ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union for the treatment of cystic fibrosis (CF) in patients aged 2 years and above who have at ...

Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO in a ...

US biotech company Vertex Pharmaceuticals (Nasdaq: VRTX) has received European Commission approval to extend the use of its ...